Wockhardt is learnt to have put its marketing division of pharmaceutical
formulations, Merind, up for sale. MNCs have shown interest in picking up the division, for which Wockhardt is learnt to have put a price tag of nearly Rs 800 crore, according to sources. Top line and EBIDTA of Merind could be Rs 300-350 crore and Rs 60-70 crore, respectively, according to sources. Wockhardt does not reveal the size of Merind’s business in its balance sheet since it is a business division.
The proposed sale is part of the troubled pharma company’s attempt to raise funds to repay debts totalling Rs 3,400 crore. Wockhardt recently sold its German subsidiary, Esparma, for Rs 120 crore, animal healthcare business for Rs 170 crore and its nutritional division for $130 million ( approximately Rs 635 crore) to raise funds. The company’s promoters, the Khorakiwala family, also sold 10 Wockhardt hospitals to Fortis for Rs 909 crore.
Merind’s is learnt to be the second largest marketing division within Wockhardt, selling more than 26 brands including top brands like Decdan, Tryptomer and Libotryb. These three brands had annual sales of Rs 21.5 crore, Rs 19.5 crore and Rs 13 crore respectively. It employs over 300 people. crackcrackCompany Name | CMP |
---|---|
Sun Pharma Inds. | 1863.85 |
Dr. Reddys Lab | 1393.30 |
Cipla | 1510.00 |
Lupin | 2232.50 |
Zydus Lifesciences | 980.70 |
View more.. |